Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune system to fight cancer by enabling durable responses and preventing tumor recurrence
Our Approach
Proprietary Technologies
Immunetune has developed unique proprietary technologies enabling next-generation best-in-class DNA vaccines against cancer and infectious diseases.
Unique Differentiators
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide and RNA vaccines and cell therapies.
Company Highlights
About Us
Company Background
Immunetune is based in Leiden, the Netherlands, and is committed to develop best-in-class vaccines and bring them to patients with a sense of purpose and urgency.
News & Events
Immunetune Strengthens Team by Appointing Sijme Zeilemaker as Chief Executive Officer
Immunetune Strengthens Team by Appointing Sijme Zeilemaker as Chief Executive Officer LEIDEN, the Netherlands, August 11, 2021 -- Immunetune, a preclinical-stage biotech developing next-generation DNA vaccines against cancer and infectious diseases, today announced...
Neoantigen Summit Europe, 20 – 22 April 2021
Our CEO, Gerben Zondag will present Immunetune's unique platform AmpliVax that enables time- and cost-efficient generation of personalized, DNA-based cancer vaccines at the upcoming digital Neoantigen Summit Europe on 20-22 Apri...
Bio-Europe Spring, 22-25 March 2021
We will attend the digital Bio-Europe Spring patnering meeting on 22 – 25 March 2021. Feel free to request a meeting if you’d like to hear more about possible partnering or investment opportunities.